Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Reference List. 2014 Authors' conclusions Twenty-two systematic reviews/meta-analyses, 24 randomized controlled trials, and three non-randomized studies were identified regarding adverse events associated with the use of apixaban and rivaroxaban. Indexing Status Subject indexing assigned by CRD MeSH Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Pyrazoles; Pyridones; Stroke; Thiophenes Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000769 Date abstract record published 09/07/2014 |